MET and non-small cell lung carcinoma: The combination of onartuzumab (MetMAb; Genentech, South San Francisco, CA), a monoclonal antibody (mAb) targeting the MET receptor 55, plus erlotinib is being evaluated in a phase 3 trial in previously treated, MET-expressing (by IHC), advanced NSCLC (NCT01456325).